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Background: Fluoropyrimidines are commonly used in metastatic breast cancer after
anthracyclines and/or taxanes failure or in frail patients. The identification of a toxicity
predictive biomarker could help to avoid severe toxicities and consequent dose
reduction or treatment discontinuation. We analyzed the predictive role on toxicity of
5-FU-DR and polymorphisms in TSER, DPYD and MTHFR genes.
Materials and methods:We collected blood samples of metastatic breast cancer
patients before starting capecitabine-based treatment. 5-FU-DR was determined by
measuring the decrease of a known dose of 5-FU incubated with peripheral blood
mononuclear cells in a time unit. Patients were classified as: poor metabolizers (PM:
5-FU-DR ≤ 0.85 ng/ml/106cells/min); normal metabolizers (NM: 0.85<
5-FU-DR > 2.2 ng/ml/106cells/min); ultra-rapid metabolizers (UM: 5-FU-DR≥ 2.2 ng/
ml/106cells/min). Gene polymorphisms of MTHFR, DPYD and TSER were detected
using DNA pyrosequensing. Toxicities were classified according to CTCAE v 3.0.
SPSS2 software was used to perform statistical analysis. Gene polymorphisms and the
5-FU-DR were correlated with toxicities through Pearson’s Chi Square test.
Results:We analyzed 40 metastatic breast cancer patients treated with capecitabine
alone or in combination regimens. 3 patients were PM, 35 were NM and 2 were UM.
Grade 3-4 toxicities were observed in 20% of patients: 50% hematopoietic, 50%
gastrointestinal, 12.5% hepatic and 12.5% hand-foot symdrome. PM and UM showed a
higher incidence of G3-4 toxicities (p = 0.05) and PM required dose reduction due to
toxicity more frequently than NM (66.7% vs 20%). No statistically significant
association between gene polymorphisms and toxicities were observed.
Conclusions: 5-FU-DR could be considered a useful toxicity predictive biomarker in
breast cancer patients treated with capecitabine-based regimens, although larger and














20 (50) 5 (25) 3 (15)
TSER
2R/2R 7 (17.5) 3 (42.9) 2 (28.6)
2R/3R 16 (40) 3 (18.8) 3 (18.8)
3R/3R 14 (35) 3 (21.4) 2 (14.3) NS
DPYD
GG 40 (100) 9 (22.5) 8 (20)
GA - - - NS
MTHFR C677T
CC 13 (32.5) 3 (23.1) 4 (30.8)
CT 20 (50) 3 (15) 4 (20)
TT 6 (15) 1 (16.7) - NS
MTHFR A1298C
AA 18 (45) 2 (11.1) 4 (22.2)
AC 17 (42.5) 5 (29.4) 2 (11.8)
CC 5 (12.5) 2 (40) 2 (40) NS
5-FU-DR
PM 3 (7.5) 2 (66.7) 2 (66.7)
NM 35 (87.5) 7 (20) 5 (14.3)
UM 2 (5) - 1 (50) 0.05
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